Loading...
Loading...
LIFE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.8M |
| Gross Profit | -0.8M |
| Operating Expense | 12.8M |
| Operating I/L | -12.8M |
| Other Income/Expense | 0.8M |
| Interest Income | 0.0M |
| Pretax | -12.0M |
| Income Tax Expense | -0.8M |
| Net Income/Loss | -11.1M |
aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines based on novel immunological pathways. The company's lead therapeutic candidate, efzofitimod, is a selective modulator of NRP2 in Phase II clinical trial for pulmonary sarcoidosis and Phase 1b/2a clinical trial for other interstitial lung diseases. Additionally, aTyr Pharma is developing ATYR2810, a fully humanized monoclonal antibody for the treatment of solid tumors. The company generates revenue through the development and commercialization of these innovative therapies, including a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for efzofitimod in Japan.
